[Treatment of visceral leishmaniasis].
A better knowledge of the mechanisms of resistance of leishmanias to drugs, of their survival strategy and the investigation of the immune mechanisms developed by the host against these parasites would be of the highest importance in the therapeutic approach of the disease, for a better use of available drugs, to try to stop the infectious process and to develop and immunotherapy and an efficient protection against the disease.
D000818:Animals; D000965:Antimony / Q000627:therapeutic use; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008536:Meglumine; D000077485:Meglumine Antimoniate; D051379:Mice; D009942:Organometallic Compounds; D010419:Pentamidine / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010419:Pentamidine; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony; D000967:Antimony Sodium Gluconate
Le traitement de la leishmaniose viscérale.